Arecor Achieves Second License Milestone Payment from Global Pharmaceutical Partner

Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.

CEO Update|Monday 24 February

Over the weekend we have seen a rise in the number of cases of Coronavirus, particularly in Italy and South Korea, leading to more disruption to travel and closure of borders. We are now hearing that there have been disruptions to India’s pharmaceutical sector, India is a key player in the export of pharmaceuticals and relies on China for 70% of its raw ingredients. The BIA is continuing to work with innovative organisations across the UK to facilitate the development and scale-up of vaccines.

Discovery Park potential recognised by Govt Life Sciences Opportunity Zone status

Discovery Park, the thriving science park for ambitious and growing life sciences companies, has been named a Life Sciences Opportunity Zone (LSOZ) by the UK Government’s Office for Life Sciences.

bioProcess UK poster presentation winner 2019

Posters have been an important factor of the annual bioProcessUK conference for the past few years. These sessions provide the opportunity for early career researchers to showcase their research, as well as themselves, in front of an audience including senior leaders across academic and industrial sectors of the UK bioprocessing community.

REVOLUTIONARY ADVANCES PROVIDED BY DIGITAL TWINS FOCUS OF EVENT AT DISCOVERY PARK

Sell-out ‘Two’s Company’ conference led by Pfizer UK, University of Kent, Kent, Surrey and Sussex AHSN

CEO Update|Monday 17 February

Boris Johnson has now confirmed his new Cabinet in a process which started with the surprise departure of Sajid Javid as Chancellor of the Exchequer.

Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has appointed Dr David Morris MD as Chief Medical Officer to lead the Company’s respiratory programmes.

Guest Blog | From open access science to open door laboratories

How unifying departments within academic institutions can increase research efficiency

CEO Update|Monday 10 February

You’ll be aware that the global battle against the coronavirus is well underway and there is important detail for member companies in this blog, about our sector’s response to the outbreak.

Guest Blog|In2scienceUK - an award winning charity looking to change the face of STEM

In 2020 the BIA is supporting the award winning charity In2scienceUK in their mission to diversify the science sector and give those with the fewest opportunities the chance to gain the experience, confidence, skills and networks to support their future career in science.